Full Breakdown
AbbVie to Acquire Apogee Therapeutics for $10.9 B, Targeting Long-Acting Immunology Asset
6/23/2026, 9:02:26 PM
AbbVie’s $10.9 B Acquisition of Apogee Therapeutics
On 22 June 2026, AbbVie Inc. announced an all-cash agreement to purchase Apogee Therapeutics Inc. for approximately $10.9 billion, or $135.11 per share. The transaction represents a premium of roughly 49-50 % to Apogee’s closing price on the day before the announcement. The deal is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
Strategic Context and Patent Pressures
AbbVie’s immunology franchise generated more than $30 billion in revenue in 2025, but sales of its former blockbuster Humira have fallen sharply after biosimilar competition, and patents for its newer immunology drugs Skyrizi and Rinvoq are set to expire in the coming years. The acquisition follows a broader wave of biopharma mergers aimed at replenishing pipelines ahead of these patent cliffs.
Key Players and Their Roles
- Robert A. Michael – Chairman and CEO of AbbVie, who framed the purchase as an “excellent fit” with the company’s strategy.
- Michael Henderson, MD – CEO of Apogee Therapeutics, who described the transaction as delivering “substantial shareholder value.”
- Blackstone Life Sciences – Provider of up to $1.3 billion in synthetic-royalty financing to Apogee, with tiered royalties that fall to zero once annual sales exceed $8 billion.
- Analysts cited include Emily Field (Barclays), Brian Abrahams (RBC Capital Markets), and Chris Schott (J.P. Morgan).
Deal Terms and Financial Highlights
- Purchase price: $135.11 per share, cash-only.
- Premium: reported as 49.5 % in most Reuters and Bloomberg accounts; one source cites a 60 % premium.
- Financing: AbbVie will fund the deal through debt; Blackstone’s synthetic-royalty facility reduces upfront cash outlay for Apogee.
- Earnings impact: AbbVie projects the acquisition to be accretive to adjusted diluted earnings per share beginning in 2032.
Clinical Promise of Zumilokibart
Apogee’s lead candidate, zumilokibart (APG777), is an IL-13-targeting monoclonal antibody designed for atopic dermatitis and asthma. Phase 2 data showed 65.9 % of patients on a mid-dose achieved a 75 % improvement in eczema severity (EASI-75) after 16 weeks, with comparable itch relief. The drug is being studied as a subcutaneous injection administered once every three or six months, a dosing interval markedly longer than the bi-weekly schedule of Dupixent (dupilumab), the current market leader.
Market Impact and Competitive Landscape
If approved, zumilokibart could compete directly with Dupixent, a Sanofi-Regeneron product that recorded $18.1 billion in global sales in 2025. AbbVie’s analysts describe the asset as having “mega-blockbuster” potential—defined as peak annual sales exceeding $10 billion. The longer dosing schedule is positioned as a convenience advantage for patients and physicians.
Official Statements & Responses
AbbVie emphasized that the acquisition “strengthens our ability to deliver innovative medicines to patients who need better options while creating long-term shareholder value.” Apogee highlighted that the deal “reflects the strength of Apogee’s vision, our team’s dedication and the significant progress we have made advancing zumilokibart.” Both companies noted the transaction will expand AbbVie’s immunology portfolio and accelerate development of combination therapies.
Criticism & Opposition
Industry observers caution that AbbVie is paying a high premium for a company with no commercial product and that the Phase 2 results may not translate to Phase 3 success. The synthetic-royalty structure, while reducing upfront cost, could impose future payment obligations if sales exceed $8 billion. Analysts also note the risk of regulatory delays and competition from established players such as Sanofi, Regeneron, and Eli Lilly.
Conflicting Reports & Gaps
Sources differ on the exact premium (49 % vs 60 %) and on the pre-offer share price ($90.38 vs $132.69). No source provides a definitive timeline for Phase 3 readout, and details of the integration plan remain undisclosed.
Verbatim Quotes
- “The acquisition of Apogee further builds on our existing leadership, strengthening our ability to deliver innovative medicines to patients who need better options while also creating significant long-term value for shareholders.” — Robert A. Michael, AbbVie
- “This transaction reflects the strength of Apogee’s vision, our team’s dedication and the significant progress we’ve made advancing zumilokibart, and our differentiated pipeline,” — Michael Henderson, CEO, Apogee Therapeutics
- “We believe AbbVie can advance zumilokibart and our portfolio while expanding their impact for patients worldwide,” — Michael Henderson, Apogee Therapeutics
- “The deal is strategically aligned with AbbVie’s focus on building its next-gen immunology franchise,” — Emily Field, Analyst, Barclays
- “For more than two decades, AbbVie has led and shaped the field of immunology, bringing the science, scale, and expertise needed to address some of the most complex diseases,” — Robert A. Michael, AbbVie
Upcoming Milestones
Phase 3 trials for zumilokibart are slated to begin in the second half of 2026, with results expected in 2028. The acquisition will close pending shareholder and antitrust approvals, after which AbbVie plans to integrate Apogee’s pipeline into its immunology development platform.
